Restricted accessReview articleFirst published online 2025
Epidemiology,characteristics,management,and survival of patients with malignant carotid body tumors: A systematic review and meta-analysis of current evidence
Malignant carotid body tumors (CBTs) represent a rare clinical entity, with existing studies limited by small sample sizes and fragmented data. This systematic review aims to: (1) Pool epidemiological estimates of malignant CBTs; (2) Characterize clinicopathological profiles; (3) Evaluate treatment modalities and survival outcomes; (4) Identify risk factors for malignant transformation.
Methods
A comprehensive search of PubMed, Scopus, Cochrane Library, and Web of Science was conducted through January 1, 2024 for literatures with malignant CBTs. The incidence, clinicopathological features, management and survival of patients with malignant CBTs were pooled analyzed and described. Benign and malignant CBTs were compared to identify any relevant risk factors of malignant transformation for CBTs. Two independent reviewers performed study selection, data extraction, and quality assessment. All statistical analyses were performed using the standard statistical procedures provided in Review Manager 5.2 and Stata 12.0.
Results
A total of 99 reports and 447 patients with malignant CBTs were identified. The pooled results indicated that the incidence of malignant CBTs was 5% (4% ‒ 6%) with a mean age of 44.11 years. In addition, female patients with malignant CBTs accounted for 61% and 14.58% experienced bilateral lesions. 74.63% malignant CBTs were defined as Shamblin III with a mean maximal diameter of 5.19 cm. We found that compared to patients with benign CBTs, patients with malignant CBTs experienced significantly higher proportion of Shamblin III (OR 4.65; 95% CI 1.80–12.06) and preoperative symptoms (hoarseness/dysphonia) (OR 7.96; 95% CI 1.79–35.5) respectively. It was observed that patients with malignant CBTs experienced more vascular and neurologic complications including vascular reconstruction or repair (OR 19.22; 95% CI 6.23–59.3), overall neurological complication (OR 3.81; 95% CI 1.28–11.36) and permanent nerve deficits (OR 3.95; 95% CI 1.26–12.41) respectively.
Conclusions
This meta-analysis established that malignant CBTs were more likely to be Shamblin III with larger size and common in middle-aged female. The majority of patients with malignant CBTs experienced preoperative systems. Preoperative hoarseness/dysphonia was associated with malignancy. Malignant CBTs increased vascular and neurologic complications. Postoperative radiotherapy was mainly used for malignant CBTs. Cohort studies with enough sample size and long follow-up are required to clear the risk factors, treatment and survival of malignant CBTs.
PellitteriPKRinaldoAMyssiorekD, et al.Paragangliomas of the head and neck. Oral Oncol2004; 40(6): 563–575.
2.
Pacheco-OjedaLA. Carotid body tumors: surgical experience in 215 cases. J Craniomaxillofac Surg2017; 45(9): 1472–1477.
3.
ParidaansMPvan der BogtKEAJansenJC, et al.Results from craniocaudal carotid body tumor resection: should it be the standard surgical approach?Eur J Vasc Endovasc Surg2013; 46(6): 624–629.
4.
ShigaKKatagiriKIkedaA, et al.Challenges of surgical resection of carotid body tumors - multiple feeding arteries and preoperative embolization. Anticancer Res2022; 42(2): 645–652.
5.
XingJChengYYingH, et al.Systemic treatment of a metastatic carotid body tumor: a case report and literature review. Medicine (Baltim)2020; 99(47): e22811.
6.
WangYHYangJZhongH, et al.Prevalence, characteristics, evaluation, and management of carotid body tumors: Systematic analysis based on available evidence. J Vasc Surg2024 Aug; 80(2): 574–585.e4. doi:10.1016/j.jvs.2024.03.443.
7.
LiYLinBLiangS, et al.Epidemiology and survival of patients with malignant carotid body tumors in the SEER database. J Vasc Surg2022; 76(4): 973–978.e1.
8.
NeumannHPErlicZBoedekerCC, et al.Clinical predictors for germline mutations in head and neck paraganglioma patients: cost reduction strategy in genetic diagnostic process as fall-out. Cancer Res2009; 69(8): 3650–3656.
9.
PasiniBStratakisCA. SDH mutations in tumorigenesis and inherited endocrine tumours: lesson from the phaeochromocytoma-paraganglioma syndromes. J Intern Med2009; 266(1): 19–42.
10.
TimmersHJGimenez-RoqueploAPMannelliM, et al.Clinical aspects of SDHx-related pheochromocytoma and paraganglioma. Endocr Relat Cancer2009; 16(2): 391–400.
11.
Review Manager (RevMan) [Computer Program]. Version 5.2. Copenhagen: the nordic Cochrane centre. The Cochrane Collaboration, 2012.
12.
NyagaVNArbynMAertsM. Metaprop: a Stata command to perform meta-analysis of binomial data. Arch Public Health2014; 72(1): 39.
13.
LauJIJIoannidisJPSchmidCH. Quantitative synthesis in systematic reviews. Ann Intern Med1997; 127(9): 820–826.
14.
University of York Centre for Reviews and Dissemination. Systematic reviews: CRD’s guidance for undertaking reviews in health care. York: CRD: University of York, 2009.
MantelNHaenszelW. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst1959; 22(4): 719–748.
17.
PageMJMcKenzieJBossuytPM, et al.The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg2021; 88: 105906.
18.
SheaBJRBReevesBCWellsG, et al.Amstar 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ2017; 358: j4008.
19.
AlfawazAAAlbloushiDQuttainehD, et al.Malignant carotid body tumor: a report of two cases. Ann Med Surg2023; 85(5): 1857–1862.
20.
AlshamsanBAtallahJP. Durable response to pazopanib in recurrent metastatic carotid body paraganglioma. Case Rep Oncol2020; 13(3): 1227–1231.
21.
AmsaluAAndersonBTesfayeW. Giant malignant carotid body tumor in a 40 years old woman: a case report from Gondar University Hospital. Ethiop Med J2013; 51(4): 285–291.
22.
ArchangMMLeeSZiuI, et al.Malignant carotid paraganglioma: a case report. Cureus2023; 15(7): e41765.
23.
AsanumaKSugenoyaATakemaeT, et al.The safe and complete removal of a carotid body tumor with elements suggestive of a malignant potential by employing an intraluminal shunt: report of a case. Surg Today1995; 25(2): 155–157.
24.
DefraigneJOLimetR. [Lymphatic, hepatic and osseous metastasis of a carotid chemodectoma. Apropos of a case]. J Chir (Paris)1997; 134(7-8): 336–339.
25.
Dias Da SilvaAO'DonnellSGillespieD, et al.Malignant carotid body tumor: a case report. J Vasc Surg2000; 32(4): 821–823.
26.
HinojosaCAAnaya-AyalaJEOlivares-CruzS, et al.Malignant Shamblin III carotid body tumors resected with use of the retrocarotid dissection technique in 2 patients. Tex Heart Inst J2018; 45(2): 92–95.
27.
JafariETabrizchiHMangeliF. Carotid body paraganglioma with prominent lymphocytic infiltration mimicking metastatic lymph node: a case report. Iran J Pathol2020; 15(1): 53–56.
28.
JeevanDSSalehMLaBagnaraM, et al.Malignant carotid body tumor presenting with myelopathy: case report. J Neurosurg Spine2016; 24(4): 660–663.
29.
KimESKimSYMoEY, et al.Novel germline SDHD mutation in a patient with recurrent familial carotid body tumor and concomitant pheochromocytoma. Head Neck2014; 36(12): E131–E135.
30.
KochCARodbardJSBrouwersFM, et al.Hypotension in a woman with a metastatic dopamine-secreting carotid body tumor. Endocr Pract2003; 9(4): 310–314.
31.
LvHChenXZhouS, et al.Imaging findings of malignant bilateral carotid body tumors: a case report and review of the literature. Oncol Lett2016; 11(4): 2457–2462.
32.
LvHLiPZhangM, et al.A case of cervical lymph node metastasis after carotid body tumor surgery. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi2022; 36(6): 475–476.
33.
MadanRJoshiNPMohantiBK, et al.Systemic metastasis in a carotid body tumor: a rare presentation of a rare tumor. South Asian J Cancer2013; 2(2): 97.
34.
MaiaMVidoedoJPintoJA. Recurrent carotid body tumors: embolization as a treatment option. Rev Port Cir Cardiotorac Vasc2014; 21(2): 129–132.
35.
MallJSaclaridesTDoolasA, et al.First report of hepatic lobectomy for metastatic carotid body tumor. J Cardiovasc Surg2000; 41(5): 759–761.
36.
MikoshibaTYoshihamaKItoF, et al.Carotid body tumor with neck metastasis due to germline SDHB variant: a case report and literature review. Int Cancer Conf J2022; 11(1): 6–11.
37.
MobergA. Malignant carotid body tumour with metastases in the lungs. Acta Otolaryngol1961; 53: 590–594.
38.
NishijimaHAsakageTSugasawaM. Malignant carotid body tumor with systemic metastases. Ann Otol Rhinol Laryngol2011; 120(6): 381–385.
39.
NorthCAZinreichESChristensenWN, et al.Multiple spinal metastases from paraganglioma. Cancer1990; 66(10): 2224–2228.
40.
Pacheco-OjedaL. Malignant carotid body tumors: report of three cases. Ann Otol Rhinol Laryngol2001; 110(1): 36–40.
41.
PatchanaTFanJJigantiM, et al.Metastatic acetabular fracture: a rare disease presentation of recurrent head and neck paraganglioma. Cureus2020; 12(4): e7596.
42.
ReeseHELucasRNBergmanPA. Malignant carotid body tumors: report of a case. Ann Surg1963; 157(2): 232–243.
43.
Rubio MaicasCDualde BeltránDFerrández IzquierdoA, et al.Malignant carotid paraganglioma: a case report. Radiologia2019; 61(2): 171–176.
44.
SallomMAl LahamOGhannamE, et al.Unilateral synchronous masses of the neck revealing a malignant Carotid Body Tumor: a case report and literature review. Int J Surg Case Rep2023; 105: 108025.
45.
TabbJNMaasJAEarlaBP, et al.Carotid body paraganglioma metastatic to spine causing cord compression: a case report. Diagn Pathol2023; 18(1): 31.
46.
UğuzMZArslanoğluSOnalK, et al.Malignant carotid body tumor: a case report. Kulak Burun Bogaz Ihtis Derg2004; 13(1-2): 38–40.
47.
WangXZhuXChenJ, et al.Metastatic brain carotid body paraganglioma with endocrine activity: a case report and literature review. Br J Neurosurg2019; 33(3): 269–271.
48.
YadavMPRajuSBallalS, et al.Complete response to 177 Lu-DOTATATE PRRT in a 9-year-old child with metastatic carotid body paraganglioma. Clin Nucl Med2024; 49(1): e33–e34.
49.
LianLLiuCGuanH, et al.[Diagnostic and therapeutic analysis of malignant carotid body tumors]. Zhonghua Yixue Zazhi2014; 94(11): 828–831.
50.
YangLLiWZhangH, et al.Clinicopathological characteristics of patients with carotid body tumor with cervical lymph node metastasis: a retrospective study of 10 cases and review of the literature. Medicine (Madr)2022; 101(36): e30379.
51.
ZhangWCZhangLWangXD, et al.[Clinical and pathological analysis of malignant carotid body tumor]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi2008; 43(8): 591–595.
52.
GuGWangYLiuB, et al.Distinct features of malignant carotid body tumors and surgical techniques for challengeable lesions: a case series of 11 patients. Eur Arch Otorhinolaryngol2020; 277(3): 853–861.
53.
ZhangWLiuFHouK, et al.Surgical outcomes and factors associated with malignancy in carotid body tumors. J Vasc Surg2021; 74(2): 586–591.
54.
AmatoBCompagnaRFlorioA, et al.Surgical versus sequential hybrid treatment of carotid body tumors. Open Med (Wars)2019; 14: 968–976.
55.
AvgerinosEDMoulakakisKBrountzosE, et al.Advances in assessment and management of carotid body tumors. Vascular2011; 19(5): 250–256.
56.
Bobadilla-RosadoLOGarcia-AlvaRAnaya-AyalaJE, et al.Surgical management of bilateral carotid body tumors. Ann Vasc Surg2019; 57: 187–193.
57.
Lozano-CoronaRAnaya-AyalaJEMartínez-MartínezR, et al.Usefulness of preoperative three-dimensional volumetric analysis of carotid body tumors. Head Neck2018; 60(12): 1281–1286.
58.
MohebaliJEdwardsHASchwartzSI, et al.Multispecialty surgical management of carotid body tumors in the modern era. Rare Tumors2021; 73(6): 2036–2040.
59.
ChenSXuJJGuGC, et al.[Risk factors for patients using intraoperative vasopressor infusions during carotid body tumor excision]. J Ultrasound2021; 43(2): 199–204.
60.
ChenWLZhouBPanCB, et al.Comparison of 3 techniques of surgical treatment of carotid body tumors. Oral Surg Oral Med Oral Pathol Oral Radiol2021; 131(6): 643–649.
61.
DaudiFAThurstonOG. Carotid body tumours: the university of Alberta hospital experience. Can J Surg1989; 32(3): 159–161.
62.
DefraigneJOSakalihassanNAntoineP, et al.Carotid chemodectomas. Experience with nine cases with reference to preoperative embolization and malignancy. Acta Chir Belg1997; 97(5): 220–228.
63.
EllisRJPatelDProdanovT, et al.The presence of SDHB mutations should modify surgical indications for carotid body paragangliomas. Ann Surg2014; 260(1): 158–162.
64.
FengYRChenXHKouXJ, et al.Individualized treatment of bilateral carotid and body tumor. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi2017; 52(1): 37–43.
65.
FruhwirthJKochGHauserH, et al.Paragangliomas of the carotid bifurcation: oncological aspects of vascular surgery. Eur J Surg Oncol1996; 22(1): 88–92.
66.
GuGWuXJiL, et al.Proposed modification to the Shamblin’s classification of carotid body tumors: a single-center retrospective experience of 116 tumors. Eur J Surg Oncol2021; 47(8): 1953–1960.
67.
HassaneinAGHassaneinKAAMFadleKN, et al.The outcome of multidisciplinary management of carotid body tumors: retrospective cohort study. J Maxillofac Oral Surg2019; 18(4): 610–616.
68.
HeisHABani-HaniKE. Carotid body tumors. Int Surg2003; 88(4): 226–230.
69.
HuHXiangYHuangB, et al.Impact of gender on the prognosis of carotid body tumor after surgical resection. J Otolaryngol Head Neck Surg2021; 50(1): 57.
70.
HuHZhaoJWuZ, et al.Level of plasma catecholamine predicts surgical outcomes of carotid body tumors: retrospective cohort study. Head Neck2019; 41(9): 3258–3264.
71.
IkedaAShigaKKatagiriK, et al.Multi-institutional survey of carotid body tumors in Japan. Oncol Lett2018; 15(4): 5318–5324.
72.
JavidHChawlaSKDyeWS, et al.Carotid body tumor: resection or reflection. Arch Surg1976; 111(4): 344–347.
73.
JiangXFangGGuoD, et al.Surgical management of carotid body tumor and risk factors of postoperative cranial nerve injury. World J Surg2020; 44(12): 4254–4260.
74.
KoskasFVignesSKhalilI, et al.Carotid chemodectomas: long-term results of subadventitial resection with deliberate external carotid resection. Ann Vasc Surg2009; 23(1): 67–75.
75.
KotelisDRizosTGeisbüschP, et al.Late outcome after surgical management of carotid body tumors from a 20-year single-center experience. Langenbecks Arch Surg2009; 394(2): 339–344.
76.
KrugerAJWalkerPJFosterWJ, et al.Important observations made managing carotid body tumors during a 25-year experience. J Vasc Surg2010; 52(6): 1518–1523.
77.
LamblinEAtallahIReytE, et al.Neurovascular complications following carotid body paraganglioma resection. Eur Ann Otorhinolaryngol Head Neck Dis2016; 133(5): 319–324.
78.
LawYChanYCChengSW. Surgical management of carotid body tumor - is Shamblin classification sufficient to predict surgical outcome?Vascular2017; 25(2): 184–189.
79.
LiZZLiangYZhangYQ, et al.[Value of head and neck CT angiography in the clinical evaluation of intraoperative bleeding volume of carotid body tumours]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao2020; 42(4): 491–496.
80.
LiapisCDEvangelidakisELPapavassiliouVG, et al.Role of malignancy and preoperative embolization in the management of carotid body tumors. World J Surg2000; 24(12): 1526–1530.
81.
Li-shanLChang-weiLHengG, et al.Efficacy of surgical therapy for carotid body tumors. Chin Med Sci J2011; 26(4): 241–245.
82.
MaHWeiMWangX, et al.Necessity of intraoperative level IIA lymph node Dissection in patients with carotid body tumors: a retrospective study of 126 cases. ORL J Otorhinolaryngol Relat Spec2021; 84(4): 271–277.
83.
MelachuriSValappilBSnydermanC. Variations in surgical outcomes of carotid body tumors by surgical specialty. Laryngoscope2021; 131(1): E190–e195.
84.
MenegoloMXodoABozzaR, et al.Improving outcomes in carotid body tumors treatment: the impact of a multidisciplinary team approach. Ann Vasc Surg2021; 75: 315–323.
85.
MitchellRORichardsonJDLambertGE. Characteristics, surgical management, and outcome in 17 carotid body tumors. Am Surg1996; 62(12): 1034–1037.
86.
MohebaliJEdwardsHASchwartzSI, et al.Multispecialty surgical management of carotid body tumors in the modern era. J Vasc Surg2021; 73(6): 2036–2040.
87.
MouradMSamanMStromanD, et al.Evaluating the role of embolization and carotid artery sacrifice and reconstruction in the management of carotid body tumors. Laryngoscope2016; 126(10): 2282–2287.
88.
MuhmMPolterauerPGstöttnerW, et al.Diagnostic and therapeutic approaches to carotid body tumors. Review of 24 patients. Arch Surg1997; 132(3): 279–284.
89.
NazariIAarabi MoghaddamFZamaniMM, et al.Clinical characteristics and remedies in 45 Iranians with carotid body tumors. Acta Med Iran2012; 50(5): 339–343.
90.
NettervilleJLReillyKMRobertsonD, et al.Carotid body tumors: a review of 30 patients with 46 tumors. Laryngoscope1995; 105(2): 115–126.
91.
NoraJDHallettJWO'BrienPC, et al.Surgical resection of carotid body tumors: long-term survival, recurrence, and metastasis. Mayo Clin Proc1988; 63(4): 348–352.
92.
O'NeillSO'DonnellMHarkinD, et al.A 22-year Northern Irish experience of carotid body tumours. Ulst Med J2011; 80(3): 133–140.
93.
OsofskyRClarkRDas GuptaJ, et al.The effect of preoperative embolization on surgical outcomes for carotid body tumor resection, Sage Open Med2021; 9: 20503121211005229.
94.
PowerAHBowerTCKasperbauerJ, et al.Impact of preoperative embolization on outcomes of carotid body tumor resections. J Vasc Surg2012; 56(4): 979–989.
95.
ReitzKRamosASperanzaG, et al.Non-functional carotid body tumors in patients without somatic mutations may Be considered for non-operative management. Ann Vasc Surg2022; 85: 57–67.
96.
Rodríguez-CuevasSLópez-GarzaJLabastida-AlmendaroS. Carotid body tumors in inhabitants of altitudes higher than 2000 meters above sea level. Head Neck1998; 20(5): 374–378.
97.
SahinMAJahollariAGulerA, et al.Results of combined preoperative direct percutaneous embolization and surgical excision in treatment of carotid body tumors. Vasa2011; 40(6): 461–466.
98.
SajidMSHamiltonGBakerDM, et al.A multicenter review of carotid body tumour management. Eur J Vasc Endovasc Surg2007; 34(2): 127–130.
99.
SarookhaniACheginiR. Carotid body tumor: our experience with 42 patients and a literature review. Indian J Otolaryngol Head Neck Surg2022; 74(3): 279–286.
100.
SenIStephenEMalepathiK, et al.Neurological complications in carotid body tumors: a 6-year single-center experience. J Vasc Surg2013; 57(2 Suppl): 64S–68s.
101.
ShaoHLiuFZhangW, et al.[Clinical features and surgical treatment of neurilemmoma versus carotid body tumors at bifurcation of carotid artery]. Head Neck2018; 47(6): 583–587.
102.
SmithJJPassmanMADattiloJB, et al.Carotid body tumor resection: does the need for vascular reconstruction worsen outcome?Ann Vasc Surg2006; 20(4): 435–439.
103.
TangHJiangXXueS, et al.Long-term surgical outcomes of carotid body tumors with pathological fibrosis: a cohort study. Front Oncol2021; 11: 684600.
104.
van Asperen de BoerFRTerpstraJLVinkM. Diagnosis, treatment and operative complications of carotid body tumours. Br J Surg1981; 68(6): 433–438.
105.
van der BogtKEVrancken PeetersMPFMvan BaalenJM, et al.Resection of carotid body tumors: results of an evolving surgical technique. Ann Surg2008; 247(5): 877–884.
106.
WangYHZhuJHYangJ, et al.The characteristics of carotid body tumors in high-altitude region: analysis from a single center. Vascular2021; 30(2): 301–309. 17085381211005238.
107.
WesterbandAHunterGCCintoraI, et al.Current trends in the detection and management of carotid body tumors. J Vasc Surg1998; 28(1): 84–92; discussion 92-3.
108.
WilliamsMDPhillipsMJNelsonWR, et al.Carotid body tumor. Arch Surg1992; 127(8): 963–968; discussion 967-8.
109.
WuZQiuPPuH, et al.Efficacy and safety of preoperative embolization in carotid body tumor treatment: a propensity score matching retrospective cohort study. Head Neck2022; 44(6): 1414–1421.
110.
YazmanSKaraagacEInerH, et al.Impact of preoperative embolization on carotid body tumor surgery. Ann Vasc Surg2022; 84: 155–162.
111.
ZhangJFanXZhenY, et al.Impact of preoperative transarterial embolization of carotid body tumor: a single center retrospective cohort experience. Int J Surg2018; 54(Pt A): 48–52.
112.
ZhangWCChengJPLiQ, et al.Clinical and pathological analysis of malignant carotid body tumour: a report of nine cases. Acta Otolaryngol2009; 129(11): 1320–1325.
113.
ZhangXZhengYLiJ, et al.Application of the shear wave elastography in the assessment of carotid body tumors: a preliminary study. Front Oncol2022; 12: 1053236.
114.
RomanskiR. Chemodectoma (non-chromaffinic paraganglioma) of the carotid body with distant metastases; with illustrative case. Am J Pathol1954; 30(1): 1–13.
115.
PiazzaCLanciniDTomasoniM, et al.Malignant carotid body tumors: what we know, what we do, and what we need to achieve. A systematic review of the literature2024; 46(3): 672–687.
116.
PatetsiosPGableDRGarrettWV, et al.Management of carotid body paragangliomas and review of a 30-year experience. Ann Vasc Surg2002; 16(3): 331–338.
117.
CarrollWStensonKStringerS. Malignant carotid body tumor. Head Neck2004; 26(3): 301–306.
118.
MayerRFruhwirthJBehamA, et al.Radiotherapy as adjunct to surgery for malignant carotid body paragangliomas presenting with lymph node metastases. Strahlenther Onkol2000; 176(8): 356–360.
119.
CooperRASlevinNJJohnsonRJ, et al.An unusual case of carotid body tumour. Clin Oncol (R Coll Radiol)1998; 10(1): 62–64.
120.
KimuraNTakayanagiRTakizawaN, et al.Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma. Endocr Relat Cancer2014; 21(3): 405–414.
121.
KohJMAhnSHKimH, et al.Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma. PLoS One2017; 12(11): e0187398.
122.
StenmanAZedeniusJJuhlinCC. The value of histological algorithms to predict the malignancy potential of pheochromocytomas and abdominal paragangliomas-A meta-analysis and systematic review of the literature. Cancers (Basel)2019; 11(2): 225.
123.
BoedekerCCNeumannHPHMaierW, et al.Malignant head and neck paragangliomas in SDHB mutation carriers. Otolaryngol Head Neck Surg2007; 137(1): 126–129.
124.
AstutiDLatifFDallolA, et al.Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet2001; 69(1): 49–54.
125.
BaysalBEFerrellREWillett-BrozickJE, et al.Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science2000; 287(5454): 848–851.
